- Home
- HAPN vs VIR Comparison
HAPN vs VIR Comparison
Compare HAPN & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HAPN | VIR |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2008 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HAPN | VIR |
|---|---|---|
| Price | $15.80 | $13.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $23.88 | $22.50 |
| AVG Volume (30 Days) | ★ 2.5M | 1.8M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.78 | 17.49 |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $314,702,000.00 | $68,556,000.00 |
| Revenue This Year | N/A | $305.75 |
| Revenue Next Year | $21.71 | N/A |
| P/E Ratio | $10.94 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.73 | $5.32 |
| 52 Week High | $21.25 | $14.38 |
Technical Indicators
Market Signals| Indicator | HAPN | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 53.65 | 63.12 |
| Support Level | $13.82 | $10.00 |
| Resistance Level | $21.25 | N/A |
| Average True Range (ATR) | 0.67 | 0.73 |
| MACD | 0.16 | 0.23 |
| Stochastic Oscillator | 67.04 | 71.49 |
Price Performance
Historical ComparisonAbout HAPN Happen Inc. Common Stock
Happen Inc is a U.S. digital marketplace bank focused on the Motivated Middle - high FICO, high-income borrowers actively managing their financial lives. The bank's success is fueled by evolved credit underwriting, a proprietary technology platform, and a marketplace bank model that generates compelling revenue through loan sales, net interest income, and fee-based services.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.